High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape

Abstract

Schaefer-Babajew, Christian Gaebler, Marina C as ke y , M ic he l C. N us se nz we ig , T he odora Hatziioannou & Paul D. BieniaszThis is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

COVID-19 vaccine strategies must focus on severe disease and global equity

“…1 , 4 According to in-vitro data from synthetic polymutant spike-protein pseudoviruses containing 20 or more mutations, vaccine boosting of infection-derived immunity might provide the strongest protection against strains like omicron. 4 , 9 …”

Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection

“…1,2 Prior infection may enhance protection from vaccination, stimulating inquiry about hybrid immunity. 3 Our objective was to examine SARS-CoV-2 spike IgG antibodies in a longitudinal cohort, comparing antibody durability in individuals who received an mRNA SARS-CoV-2 vaccine with or without prior SARS-CoV-2 infection.…”

Clinical practice in COVID-19: The most frequently asked questions to infectious diseases specialists

“…In addition to the aforementioned, there is recent evidence that a single dose of mRNA vaccines in subjects post-SARS-CoV-2 infection results in a significant increase in serum NAb responses, including protection against emerging variants 74 , 75 , 76 .…”